<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 11, 2000
-------------------------------
Oak Technology, Inc.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 0-25298 77-01614
- --------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
139 Kifer Court, Sunnyvale, California 94086
- -------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Company's telephone number, including area code: (408) 737-0888
-------------------------------
- -------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS
Pursuant to an Agreement and Plan of Merger and Reorganization (the
"Merger Agreement"), dated July 29, 1999, among the Registrant, Vermont
Acquisition Corp., a Delaware corporation and a wholly-owned subsidiary of the
Registrant ("Merger Sub"), and Xionics Document Technologies, Inc., a Delaware
corporation ("Xionics"), Xionics merged with and into Merger Sub and became a
wholly-owned subsidiary of the Registrant effective on January 11, 2000 (the
"Merger"). On January 11, 2000, at an annual meeting of the stockholders of Oak,
the stockholders of Oak approved the issuance of the shares of Oak common stock
to be issued to the former Xionics stockholders in connection with the Merger
and the amendment of the certificate of incorporation of Oak to increase the
number of shares of common stock which Oak is authorized to issue to 130 million
shares.
In connection with the Merger, Xionics stockholders will receive the
right to receive .8031 of a share of the Registrant's common stock and $2.94
cash for each share of Xionics common stock owned. As a result of the Merger,
Oak will issue approximately 9.4 million shares of Oak common stock to the
former Xionics stockholders and will pay approximately $34.4 million in cash to
the former Xionics stockholders as a part of the merger consideration. Funds for
the cash portion of the merger consideration were obtained from Oak's existing
working capital.
In addition to the foregoing, in accordance with the provisions of the
Merger Agreement, the Registrant has agreed to issue options to purchase shares
of its common stock in exchange for options to purchase shares of Xionics common
stock issued by Xionics pursuant to its stock option plans prior to the Merger.
Each such option so assumed by Registrant under the Merger Agreement will
continue to have, and be subject to, the same terms and conditions set forth in
the related Xionics stock option plan and the applicable stock option agreement
immediately prior to the effective time of the Merger, except that such option
will be exercisable for a number of shares of Registrant common stock equal to
the product of the number of shares of Xionics common stock that were issuable
upon exercise of such option immediately prior to the effective time multiplied
by 1.5748. Notwithstanding this arrangement, the Registrant has agreed, if
practicable and if requested by the holder of a Xionics' stock option assumed by
Registrant that is exercisable to any extent at the effective time of the Merger
(the Xionics common stock as to which any such option is then exercisable, the
"Vested Shares"), to pay the holder of such Xionics stock option an amount of
cash equal to the cash which the holder would have received on an exchange of
the Vested Shares in the Merger in consideration of a reduction in the number of
shares covered by the holder's Xionics stock option assumed by Registrant to the
number of shares of Registrant common stock the holder would have received on an
exchange of the Vested Shares pursuant to the Merger without any change in the
aggregate exercise price from the exercise price in effect prior to assumption.
Xionics is a provider of digital page processing software and technology
for the digital office market. Xionics also provides other types of embedded
software such as device drivers for copiers, fax scanners and multifunctional
peripherals.
<PAGE>
The Registrant is not aware of any pre-existing material relationship
between the former stockholders of Xionics and the Registrant, or between such
stockholders and the Registrant's affiliates, officers or directors or any
associates of any such officers or directors.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(a) Financial Statements of Business Acquired.
The financial statements of Xionics are incorporated by reference to
(i) the Annual Report on Form 10-K/A filed by Xionics with the Securities and
Exchange Commission on December 9, 1999 and (ii) the Quarterly Report on Form
10-Q for the three-month period ended September 30, 1999 filed by Xionics
with the Securities and Exchange Commission on November 12, 1999.
(b) Pro Forma Financial Information.
The following unaudited pro forma combined condensed financial
statements are presented for illustrative purposes only and are not necessarily
indicative of the combined financial position or results of operations for
future periods or the results of operations or financial position that actually
would have been realized had the Registrant and Xionics been a combined company
during the specified periods. The unaudited pro forma combined condensed
financial statements, including the related notes, are qualified in their
entirety by reference to, and should be read in conjunction with, the historical
consolidated financial statements of the Registrant and Xionics, including the
related notes.
The following unaudited pro forma combined condensed financial
statements give effect to the merger between the Registrant and Xionics using
the purchase method of accounting. The pro forma combined condensed financial
statements are based on the respective historical consolidated financial
statements and related notes of the Registrant and Xionics, which are
incorporated by reference into this document or included elsewhere in this
document. The pro forma adjustments are preliminary and based on management of
the Registrant's estimates of the value of the tangible and intangible assets
acquired. In addition, management of the Registrant is in the process of
assessing and formulating its integration plans, which may include employee
separations, employee relocations, and other restructuring actions and has not
yet determined the costs, if any, of these plans.
Based on the timing of the closing of the transaction, the finalization
of the integration plans and other factors, the pro forma adjustments may differ
materially from those presented in these pro forma financial statements. A
change in the pro forma adjustments would result in a reallocation of the
purchase price affecting the value assigned to the long-term tangible and
intangible assets or, in some circumstances, result in a change to the statement
of operations. The effect of these changes on the statement of operations will
depend on the nature and amounts of the assets and liabilities adjusted. See
note (1) to the pro forma combined condensed financial statements.
3
<PAGE>
The unaudited pro forma combined condensed balance sheet assumes that
the merger took place on September 30, 1999, and combined the Registrant's
unaudited September 30, 1999 consolidated balance sheet with Xionics' unaudited
September 30, 1999 consolidated balance sheet. The pro forma combined condensed
statements of operations assume the merger took place as of July 1, 1998 and
combines the Registrant's consolidated statement of operations for the
year ended June 30, 1999 and consolidated statement of operations for
the three months ended September 30, 1999, with Xionics' statement of
operations for the year ended June 30, 1999 and its consolidated
statement of operations for the three months ended September 30, 1999.
4
<PAGE>
UNAUDITED PRO FORMA COMBINED CONDENSED BALANCE SHEET
SEPTEMBER 30, 1999
(IN THOUSANDS)
<TABLE>
<CAPTION>
REGISTRANT XIONICS ADJUSTMENTS COMBINED
---------- ------- ----------- --------
SEPTEMBER 30, 1999 SEPTEMBER 30, 1999
------------------ ------------------
HISTORICAL PRO FORMA
---------- ---------
<S> <C> <C> <C> <C>
Current assets:
Cash and cash equivalents............................... $13,563 $24,438 $(34,391)(a) $3,610
Short-term investments.................................. 113,710 113,710
Accounts receivable, net................................ 5,421 4,830 (1,000)(a) 9,251
Contract receivable..................................... 0 4,000 4,000
Inventories............................................. 1,558 - - 1,558
Current portion of foundry deposits..................... 5,192 - - 5,192
Prepaid expenses and other current assets............... 12,463 7 - 12,470
Total current assets.................................... 151,907 33,275 (35,391) 149,791
Property and equipment, net............................... 21,718 1,932 - 23,650
Foundry deposits.......................................... 7,760 - - 7,760
Intangible assets......................................... 0 - 23,516 (a) 23,516
Goodwill.................................................. 0 - 26,145 (a) 26,145
Deferred tax asset........................................ 0 1,030 (1,030)(b) -
Other assets.............................................. 9,074 1,203 - 10,277
Total assets.............................................. $190,459 $37,440 $13,240 $241,139
Current liabilities:
Notes payable and current portion of long-term debt..... $26 $ - - $26
Accounts payable........................................ 4,248 1,148 5,396
Accrued expenses........................................ 7,092 8,374 1,200 (a) 16,666
Deferred revenue........................................ 234 6,907 (2,000)(a) 5,141
Total current liabilities............................... 11,600 16,429 (800) 27,229
Deferred income taxes..................................... 1,438 - - 1,438
Other long-term liabilities............................... 342 - - 342
Total liabilities....................................... 13,380 16,429 (800) 29,009
Stockholders' equity:.....................................
Common stock............................................ 43 130 (118)(a) 55
Additional paid-in capital.............................. 165,660 47,479 (2,583)(a) 210,556
Retained earnings....................................... 21,847 (22,491) 12,643 (a) 11,990
Treasury stock.......................................... (10,471) (4,107) 4,107 (a) (10,471)
Total stockholders' equity.............................. 177,079 21,011 14,040 212,130
Total liabilities and stockholders' equity.............. $190,459 $37,440 $13,240 $241,139
</TABLE>
5
<PAGE>
UNAUDITED PRO FORMA COMBINED CONDENSED STATEMENT OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<TABLE>
<CAPTION>
REGISTRANT XIONICS ADJUSTMENTS COMBINED
---------- ------- ----------- --------
1999 HISTORICAL PRO FORMA
--------------- ---------
YEAR ENDED JUNE 30, 1999
------------------------
<S> <C> <C> <C> <C>
Net revenues............................................... $71,051 $31,403 $(95)(c) $102,359
Costs and expenses:
Cost of revenues......................................... 39,619 9,747 (95)(c) 49,271
Research and development expenses........................ 51,107 12,198 - 63,305
Selling, general, and administrative expenses............ 35,109 7,104 - 42,213
In-process research and development expenses............. 7,161 - - 7,161
Amortization of goodwill and other intangible assets..... - - 12,222 (d) 12,222
Total cost and expenses.................................. 132,996 29,049 12,127 174,172
Operating income (loss).................................. (61,945) 2,354 (12,222) (71,813)
Non-operating income, net.................................. 5,530 753 - 6,283
Income (loss) before income taxes........................ (56,415) 3,107 (12,222) (65,530)
Income taxes (benefit)..................................... (5,747) 290 - (5,457)
Net income (loss)........................................ $(50,668) $2,817 $(12,222) $(60,073)
Pro forma net income (loss) per share:
Basic and diluted.......................................... $(1.24) $(1.20)
Shares used in computing net income (loss) per share:
Basic and diluted.......................................... 40,819 -- 9,394 (e) 50,213
</TABLE>
6
<PAGE>
UNAUDITED PRO FORMA COMBINED CONDENSED STATEMENT OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<TABLE>
<CAPTION>
REGISTRANT XIONICS ADJUSTMENTS COMBINED
---------- ------- ----------- --------
HISTORICAL PRO FORMA
---------- ---------
THREE MONTHS ENDED SEPTEMBER 30, 1999
-------------------------------------
<S> <C> <C> <C> <C>
Net revenues............................................... $10,142 8,981 - $19,123
Costs and expenses:
Cost of revenues......................................... 5,071 2,754 - 7,825
Research and development expenses........................ 12,139 2,862 - 15,001
Selling, general, and administrative expenses............ 7,463 1,946 - 9,409
Amortization of goodwill and other intangible assets..... - 3,008 (d) 3,008
Total cost and expenses.................................. 24,673 7,562 3,008 35,243
Operating income (loss).................................. (14,531) 1,419 (3,008) (16,120)
Non-operating income, net.................................. 2,345 254 - 2,599
Income (loss) before income taxes........................ (12,186) 1,673 (3,008) (13,521)
Income taxes (benefit)..................................... - 225 - 225
Net income (loss)........................................ $(12,186) $1,448 $(3,008) $(13,746)
Pro forma net income (loss) per share:
Basic and diluted.......................................... $(0.30) - - $(0.27)
Shares used in computing net income (loss) per share:
Basic and diluted.......................................... 41,086 - 9,394 (e) 50,480
</TABLE>
NOTES TO UNAUDITED PRO FORMA COMBINED CONDENSED FINANCIAL STATEMENTS
(1) UNAUDITED PRO FORMA COMBINED CONDENSED BALANCE SHEET
On July 29, 1999, the Registrant entered into a merger agreement under
which all of the outstanding common stock of Xionics is to be exchanged for cash
and common stock of the Registrant. Each Xionics stockholder will receive $2.94
cash and .8031 shares of the Registrant common stock for each share of Xionics
common stock. In addition, the Registrant will assume all outstanding options to
purchase Xionics common stock. Under the merger agreement, holders of Xionics
options that are exercisable, may elect to receive an option to purchase 1.5748
shares of
7
<PAGE>
the Registrant's common stock or $2.94 cash and an option to purchase .8031
shares of the Registrant's common stock for each vested option. Vested and
unvested options were valued using the Black-Scholes option pricing model. The
actual number of the Registrant's shares and cash to be issued will depend upon
the choice of vested option holders. Accordingly, the actual allocation of the
purchase price could differ from that presented below.
The pro forma combined condensed balance sheet as of September 30, 1999,
gives effect to the merger as if it had occurred on September 30, 1999.
The following adjustments have been reflected in the unaudited pro forma
combined condensed balance sheet:
(a) To record cash paid and common stock and options issued to Xionics
stockholders and record applicable purchase accounting entries. The fair value
of the Registrant's common stock issued and vested options assumed was
determined using the weighted average market price of the Registrant's common
stock two days before and after the merger was publicly announced. The fair
value of all options was determined using the Black-Scholes model.
Under purchase accounting, the total purchase price will be allocated to
Xionics' assets and liabilities based on their fair values. Allocations are
subject to valuations as of the date of the consummation of the merger. The
amounts and components of the estimated purchase price along with the
preliminary allocation of the estimated purchase price to assets purchased are
as follows (in thousands):
<TABLE>
<CAPTION>
<S> <C>
Cash.......................................................................... $34,391
Common stock.................................................................. 36,450
Fair value of Xionics stock options assumed................................... 8,458
Total purchase price........................................................ $79,299
Fair value of net tangible assets of Xionics.................................. $19,780
Intangible assets............................................................. 23,516
Goodwill...................................................................... 26,145
Purchase of in-process research and development............................... 9,858
Total net tangible and intangible assets acquired........................... 79,299
</TABLE>
The actual allocation of the purchase price will depend upon the
composition of Xionic's net assets on the closing date and the Registrant's
evaluation of the fair value of the net assets as of the date indicated.
Consequently, the actual allocation of the purchase price could differ from that
presented above.
8
<PAGE>
<TABLE>
<S> <C>
Intangible assets include (in thousands):
Developed Technology................................................................. $9,593
Core Technology...................................................................... 9,025
Acquired Workforce................................................................... 2,766
Patents.............................................................................. 1,448
Tradename............................................................................ 684
$23,516
</TABLE>
Based on a preliminary allocation of the purchase price, the
Registrant expects to take a special charge of approximately $10 million
against earnings in the quarter in which the merger occurs in order to
write-off the cost of in-process research and development. At the valuation
date, Xionics had several in-process research and development projects in
each of its product groups: languages, drivers, MFPs and its new Tandem
product. The majority of Xionics' research and development activities are
focused on advancing Xionics' products in the areas of increased performance
and color, enabling multifunction peripherals (combining print, copy, scan
and fax capabilities), and providing improved internet printing and network
connectivity. In driver technology, Xionics is working on an integrated
development environment capable of creating customized printer drivers
supporting Microsoft Windows operating systems. Each of these projects has
not yet achieved technological feasibility. As image processing represents a
very specialized market, it is unlikely that Xionics' in-process technology
could be successfully deployed in alternative market applications. Further,
it was determined that there was significant technological risk and
substantial future development expenses relating to each of the products
under development. However, the Registrant's management believes that Xionics
will be successful in completing development of their in-process products
based on their considerable expertise and know-how in imaging technology.
Delays in or failure to complete the development of in-process products could
seriously harm the Registrant's business, results of operations and financial
condition. Research and development expenses are expected to remain at or
above current levels of approximately $12 million per year in order to
support these on-going development activities. Through discussions with
Xionics technical personnel, it was determined that the in-process products
will utilize some technology from previous products, or existing know-how.
This is referred to as core technology, the value of which is used to
estimate the amount of developed technology that can be leveraged and
utilized in conjunction with the new, in-process technology to develop the
in-process products. The core technology leverage factor ranged from 0% to
35% and was extracted in order to value the core and in-process technologies
separately. Expected revenues from in-process products are expected to
commence in fiscal year 2000 and will comprise the majority of Xionics'
revenues over the next several years.
The valuation of the acquired in-process research and development used
by the Registrant in making the determination as to the amount of in-process
research and development was supported by valuation studies prepared by an
independent third-party appraiser. The estimated value of in-process research
and development was derived using the "Income Approach," which values an asset
based on future cash flows that could potentially be generated by the asset over
its estimated useful life. The future cash flows were discounted to their
present value utilizing a discount rate of 24%. The amounts of the purchase
price technology assigned to the fair values of in-process research and
development and purchased technology represent management's best estimate. The
Registrant does not anticipate any material changes from historical pricing,
margins and expense levels in its valuation assumptions.
9
<PAGE>
(b) The pro forma financial information includes a pro forma adjustment
to reflect the impact of establishing a valuation allowance against Xionics
deferred tax assets at June 30, 1999. This allowance would have been required
had the companies been combined.
(2) UNAUDITED PRO FORMA COMBINED CONDENSED STATEMENTS OF OPERATIONS
The pro forma combined condensed statements of operations give effect
to the merger as if it had occurred at the beginning of the period presented.
The pro forma condensed statement of operations does not include the
write-off of in-process research and development of approximately $10 million.
The following adjustments have been reflected in the unaudited pro forma
combined condensed statements of operations:
(c) Adjustment to eliminate intercompany transactions between the Registrant and
Xionics.
(d) Adjustment to record the amortization of goodwill and intangible assets
resulting from the allocation of the Xionics purchase price. The pro forma
adjustment assumes goodwill and other intangible assets will be amortized on a
straight-line basis over an estimated life between 3 and 5 years. The ultimate
lives assigned will be determined at the date of acquisition based on the facts
and circumstances existing at that date. A preliminary determination of useful
lives for each category of intangible asset is as follows: developed technology,
3 years; core technology, 4 years; acquired workforce, 3 years; patents, 5
years; tradename, 5 years.
(e) To reflect the estimated shares to be issued as consideration for the merger
based on the ratio of .8031 shares of the Registrant's common stock for each
outstanding share of Xionics common stock.
(c) Exhibits
<TABLE>
<CAPTION>
Number Description
------ -----------
<S> <C>
12.1 Agreement and Plan of Merger and Reorganization, dated July 29,
1999, by and among Oak Technology, Inc., Xionics Document
Technologies, Inc. and Vermont Acquisition Corp. included as
Appendix A to the Registrant's Registration Statement on Form
S-4 (Registration No. 333-92541) and incorporated by reference.
99.1 Press release of the Registrant dated January 14, 2000
(announcing the completion of the merger)
</TABLE>
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to
be signed on its behalf by the undersigned, duly authorized officer.
OAK TECHNOLOGY, INC.
By: /s/ Young K. Sohn
---------------------------------------------
Name: Young K. Sohn
Title: President and Chief Executive Officer
10
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit
Number Exhibit Title
------ -------------
<S> <C>
12.1 Agreement and Plan of Merger and Reorganization, dated July 29,
1999, by and among Oak Technology, Inc., Xionics Document
Technologies, Inc. and Vermont Acquisition Corp. included as
Appendix A to the Registrant's Registration Statement on Form
S-4 (Registration No. 333-92541) and incorporated by reference.
99.1 Press release of the Registrant dated January 14, 2000
(announcing the completion of the merger)
</TABLE>
11
<PAGE>
EXHIBIT 99.1
OAK TECHNOLOGY COMPLETES ACQUISITION OF XIONICS
ANNOUNCES MANAGEMENT TEAM, FORMER CEO OF XIONICS TO JOIN OAK BOARD
SUNNYVALE, CA.-January 12, 2000 -- Oak Technology (NASDAQ:OAKT)
announced today that it has completed the acquisition of Xionics Document
Technologies. Shareholders of both companies yesterday voted to approve the
acquisition agreement, which was made between the two companies in July 1999.
The operations of Xionics will be merged with Oak's existing imaging
operations to form the Oak Imaging Group. The group will be based in the suburbs
of Boston, where both Xionics and Oak's imaging operations are currently based.
Through this strategic merger with Xionics, Oak solidifies its leadership in
both image processors and embedded software, creating one of the most
comprehensive suppliers of both hardware and software technology and solutions
for the digital office equipment market. This combination enhances Oak's
position as a strategic partner and supplier to the top OEMs in digital office
equipment, which include, among others, Canon, FujiXerox, Hewlett-Packard, IBM,
Ricoh, Seiko Epson, Sharp and Xerox.
Pete Simone, formerly Chief Executive Officer of Xionics, has joined
the Board of Directors of Oak Technology. "This acquisition makes great
strategic sense and I am glad that I will be able to continue to play a role in
Oak's future by joining the Board," commented Mr. Simone.
MANAGEMENT TEAM
A team of industry veterans will manage the Oak Imaging Group. Peter
Besen, formerly President of Oak's Pixel Magic subsidiary, will be Vice
President and General Manager for Image Processing Products; Rosemary Grande,
formerly Chief Operating Officer of Xionics, is named to the post of Vice
President and General Manager of Software Products. Simon Dolan, currently Vice
President of Corporate Marketing and Strategy at Oak Technology, adds Imaging
Marketing to his duties. John Seguin, formerly Vice President of Sales and
Marketing at Xionics is named to the post of Vice President of Sales for the
Imaging Group. Besen, Dolan and Grande report directly to Young Sohn, President
and CEO of Oak Technology. Mr Seguin reports to Charlie Parr, Vice President of
Worldwide Sales for Oak Technology. Don Shulsinger, formerly Vice President of
Sales and Marketing for Pixel Magic, joins the team as Vice President of
Internet Business Development, reporting directly to Mr. Sohn. Bob Lentz,
formerly Senior Vice President and Chief Financial Officer of Xionics, will stay
with the company on an interim basis to help drive the successful merger of the
two companies.
"Now that this acquisition has closed, we can move ahead with our plans
to integrate the two companies," said Mr. Sohn. "The combination of Xionics'
strengths in software and Oak's chip expertise will allow us to offer a broad
range of solutions for the future connected office. We have assembled a
management team from both companies that has the skills and experience to take
Oak Imaging to the next level. I am particularly pleased to be able to add Pete
Simone's experience and expertise in the imaging world to our board of
directors."
<PAGE>
TERMS OF THE AGREEMENT
Under the terms of the agreement, Xionics shareholders will receive
.8031 share of Oak common stock for each share of Xionics stock and $2.94 in
cash. Oak will assume Xionics' outstanding options. Xionics has approximately
11.5 million shares outstanding. The company expects to incur a one-time charge
to earnings for the quarter ending March 31, 2000 of approximately $16 million,
which includes in-process research and development, estimated costs to
consolidate facilities and operations, and other expenses related to the
acquisition.
ABOUT XIONICS
Xionics is the leading developer of innovative software and silicon for
printing, scanning, copying, processing and transmitting documents to computer
peripherals. Xionics partners with the industry's leading OEMs, including
Hewlett-Packard, IBM, QMS, Ricoh, Samsung, GCC, Seiko Epson, Sharp, and Xerox,
to develop peripherals that provide the performance, output quality and network
connectivity for today's office computing market. The company's corporate
headquarters is based in Burlington, Mass., with offices in Japan and Germany.
For more information on Xionics and its products, visit the company on the at
World Wide Web at www.xionics.com.
ABOUT OAK TECHNOLOGY
Founded in 1987, Oak Technology, Inc. designs, develops and markets
high-performance semiconductors and related software to original equipment
manufacturers (OEMs) worldwide who serve the optical storage, consumer
electronics and digital office equipment markets. Oak has subsidiaries in Japan
(Oak Technology K.K.); Taiwan (Oak Technology, Taiwan); and Andover, Mass.
(Oak's Imaging Group). The Company completed its initial public offering in
February 1995. Additional information about Oak Technology and its products can
be found on the World Wide Web at www.oaktech.com.
###
Oak Technology and the Oak logo are registered trademarks of Oak
Technology, Inc., All other product names or company names are mentioned for
identification purposes only, and may be trademarks of their respective owners.
Editorial Contact
Simon Dolan
Oak Technology, Inc.
(408) 523 6506
[email protected]
Mark J. Ferrone
Brodeur Worldwide
(408) 273-7245
[email protected]
